Congress Materials - Travere Medical Affairs

Media, investors, advocacy organizations and others, please contact us here.

Congress material NephrologyIgAN

Effect of Sparsentan Following Treatment With ARB in IgA Nephropathy Patients in the Phase 3 PROTECT Trial

In the open-label extension (OLE) of the Phase 3 PROTECT trial, safety and efficacy was assessed after patients in the irbesartan arm switched to sparsentan.

Learn more

MA-DS-25-0105 | October 2025

Congress material NephrologyIgAN

Sparsentan Added to Stable SGLT2is in Patients with IgA Nephropathy:
Final Results From the Phase 2 SPARTACUS Trial

In the Phase 2 SPARTACUS trial, safety and efficacy of replacing RASi with sparsentan was assessed in patients receiving stable SGLT2i therapy.

Learn more

MA-DS-25-0105 | October 2025

Congress material NephrologyFSGS

Effect of Sparsentan vs Irbesartan on Proteinuria Targets in Patients With FSGS in the Phase 3 DUPLEX Trial

An analysis of the Phase 3 DUPLEX trial investigated the impact of sparsentan vs irbesartan on safety, proteinuria remission, and progression to kidney failure.

Learn more

MA-SP-25-0160 | September 2025

Explore our congress materials

Encore posters are re-presentations of previously published data.

Results123

Presentation NephrologyIgAN

Outcomes of Renal Transplantation in Primary Glomerulonephritis (GN) Mapped to Post-Transplant Proteinuria in the UK RaDaR Registry

American Society of Nephrology (ASN) Kidney Week – 2025

Presentation NephrologyIgAN

Real-World Data on Low Proteinuria With Sparsentan (SPAR) in Patients (Pts) With IgA Nephropathy (IgAN): A Case Series

American Society of Nephrology (ASN) Kidney Week – 2025

Poster NephrologyIgAN

Real-World Data on Low Proteinuria With Sparsentan (SPAR) in Patients (Pts) With IgA Nephropathy (IgAN): A Case Series

American Society of Nephrology (ASN) Kidney Week – 2025

Presentation NephrologyIgAN

Case Series: Proteinuria Reductions With Sparsentan (SPAR) Combined With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) at a Single Site

American Society of Nephrology (ASN) Kidney Week – 2025

Poster NephrologyIgAN

Case Series: Proteinuria Reductions With Sparsentan (SPAR) Combined With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) at a Single Site

American Society of Nephrology (ASN) Kidney Week – 2025

Summary NephrologyIgAN

PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy

American Society of Nephrology (ASN) Kidney Week – 2025

MSL CTA Image

Connect with our MSL team today

Arrange a meeting with a member of our medical science liaison (MSL) team to discuss the latest insights, clinical trial data, and management trends.